- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07947095
Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms (CHIME)
Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms: Randomized Controlled Trial (CHIME Trial)
The goal of this clinical trial is to find out if calisda, a digital health intervention, can help women with menopause symptoms manage their symptoms and improve their quality of life.
The main questions it aims to answer are:
- Does calisda, together with regular treatment, improve health outcomes after six months better than regular treatment alone?
- Are the positive effects of calisda already noticeable after three months?
Researchers will compare two groups:
- Intervention group: Participants use the calisda intervention and continue their usual treatment.
- Control group: Participants continue with their usual treatment only.
Participants will:
- Fill out questionnaires online at the start of the study, after 3 months, and after 6 months
- Continue with their usual treatment (both groups) and use calisda, a digital health intervention, for six months (intervention group only)
연구 개요
상세 설명
This pragmatic, two-arm randomized controlled trial evaluates the effectiveness of calisda, a certified medical device (CE-marked, risk class I), when used alongside regular treatment. The study compares the addition of this digital health intervention to treatment as usual (TAU) against TAU alone. Designed as an interactive online program, calisda incorporates recognized elements of cognitive behavioral therapy (CBT), behavior change, and patient education.
After confirming eligibility, participants are randomly assigned to one of two groups. The intervention group receives immediate access to calisda for six months alongside their usual treatment. The control group continues their regular treatment and is granted access to the intervention after a six-month waiting period.
Data is collected from both groups via online questionnaires at the start of the study, after three months, and after six months. The primary evaluation of effectiveness will be conducted at the six-month follow-up. Data collected at the three-month mark will be utilized to assess early treatment response.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Anja Specht, MSc.
- 전화번호: +49 40 3510520
- 이메일: anja.specht@gaia-group.com
연구 연락처 백업
- 이름: Clara Ekerdt, PhD
- 전화번호: +49 40 351052 135
- 이메일: clara.ekerdt@gaia-group.com
연구 장소
-
-
-
Hamburg, 독일
- GAIA AG
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Female biological sex
- Age 40-65 years
- Diagnosis of menopause symptoms (ICD-10 code: N95.1) confirmed by a medical document
- Increased levels of menopause symptoms (MRS-II total score ≥ 14)
- Reduced menopause-specific quality of life (MENQOL total score ≥ 3)
- Stable symptom-related treatment (medication, psychotherapy, no treatment, …) for at least 60 days at the time of inclusion
- Sufficient knowledge of the German language
- Basic computer skills required for independent use of a digital intervention
- Consent to participation
Exclusion Criteria:
- Plans to change symptom-related treatment (medication, psychotherapy, …) in the upcoming 6 months after inclusion
- Current or history of any malignancy except for basal and squamous cell skin tumors
- Current HRT use
- Premature, medically induced menopause (e.g. following bilateral oophorectomy)
- Known somatic or psychiatric condition that might interfere with successful study participation (e.g. unstable neurologic or psychiatric disorder)
- Previous use of a digital intervention for menopause symptoms (including calisda) or another digital intervention developed by GAIA.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: calisda
Participants will receive access to the digital health intervention calisda in addition to TAU. |
Participants allocated to the intervention group will receive access to calisda in addition to treatment as usual (TAU). calisda is a digital health intervention designed for women with menopause symptoms, accessible through a web browser. The program focuses on treatment methods derived from cognitive behavioral therapy (CBT), health behavior change, and patient education. Topics addressed by calisda include understanding menopausal changes and symptoms, coping with hot flashes and night sweats, sleep, mood, self-acceptance and self-worth, relationship communication, as well as information on hormone therapy and complementary approaches. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their progress. Once registered, the program remains accessible for six months. |
|
간섭 없음: Control group
Participants allocated to the control group will receive access to treatment as usual (TAU). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
29-item Menopause-Specific Quality of Life Questionnaire (MENQOL; 1-week recall) total score
기간: 6 months
|
The MENQOL is a patient-reported outcome measure (PROM) with 29 items. Each item uses a two-stage response format. This questionnaire consists of four domains, with varying item numbers: "vasomotor", "psychosocial", "physical" and "sexual". To obtain the total score, the mean of the domain scores is computed. Both the domain and the total scores range from 1 to 8. Higher total scores indicate greater impairment of quality of life. |
6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Hot Flash Related Daily Interference Scale (HFRDIS) total score
기간: 6 months
|
The HFRDIS is a 10-item PROM assessing the extent to which hot flashes interfere with daily activities and overall quality of life over the past week. Each item is rated from 0 ("did not interfere") to 10 ("completely interfere"). The total score is the mean of all items and ranges from 0 to 10. Higher total scores indicate greater hot flash interference and thus a worse outcome, whereas lower scores indicate less interference and a better outcome. |
6 months
|
|
Insomnia Severity Index (ISI) total score
기간: 6 months
|
The ISI is a 7-item PROM assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point scale from 0 to 4. The total score is the sum of all items and ranges from 0 to 28. Higher total scores indicate greater insomnia severity and thus a worse outcome, whereas lower scores indicate less insomnia severity and a better outcome. |
6 months
|
|
Patient Health Questionnaire (PHQ-9) total score
기간: 6 months
|
The PHQ-9 is a 9-item PROM assessing the severity of depressive symptoms. Each item is scored from 0 ("not at all") to 3 ("nearly every day"). The total score is the sum of all items and ranges from 0 to 27. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome. |
6 months
|
|
Menopause Rating Scale II (MRS-II) total score
기간: 6 months
|
The MRS-II is an 11-item PROM assessing the severity of menopause-related symptoms. Each item is rated from 0 ("no complaints") to 4 ("very severe symptoms"). The total score is the sum of all items and ranges from 0 to 44. Higher total scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome. |
6 months
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Philipp Klein, Prof. Dr. med., Universität zu Lübeck, Zentrum für Integrative Psychiatrie ZiP gGmbH
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- calisda RCT 2026
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .